Innoviva (INVA) Specialty Therapeutics, a subsidiary of Innoviva, announced the United States commercial availability of ZEVTERA, the newest addition to the company’s growing antibiotic portfolio. ZEVTERA is the only U.S. FDA approved advanced-generation cephalosporin indicated to treat adult patients with Staphylococcus aureus bloodstream infection, including those with right-side endocarditis caused by methicillin-susceptible and methicillin-resistant isolates. ZEVTERA is the latest approved MRSA SAB therapy since 2006.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INVA: